Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.46 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.46 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL28066305 | 1.00 | SLC1A1 (0.54) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL108340 | 1.00 | SLC1A1 (0.54) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL23675448 | 0.93 | SLC1A1 (0.48) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL10446032 | 0.93 | SLC1A1 (0.48) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL9716104 | 0.91 | SLC7A5 (0.50) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL3442616 | 0.91 | SLC7A5 (0.50) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Asparagine SCHEMBL25397698 | 0.91 | SLC1A1 (0.47) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL8671844 | 0.89 | GRIK1 (0.52) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL11065189 | 0.89 | GRIK1 (0.56) | SLC1A1GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL11065185 | 0.89 | GRIK1 (0.56) | SLC1A1GRIK1GRIK2GRM1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076477-A1 | STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | claimed |
| CN-104379598-A | Highly glycosylated long-acting human growth hormone protein and production method for same | CJ CHEILJEDANG CORP | 2015-02-25 | — | — | CN | claimed |
| EP-1034277-A2 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) | Inhibitex, Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| WO-1999027109-A2 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) | INHIBITEX, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-20250188135-A1 | A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE COMPRISING B- AND T-CELL ANTIGENS, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025076477-A1 | STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4489776-A2 | A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE COMPRISING B- AND T-CELL ANTIGENS, IMMUNOGENIC COMPOSITION, AND USES THEREOF | The Children's Medical Center Corporation (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023172741-A2 | A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE COMPRISING B- AND T-CELL ANTIGENS, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230192863-A1 | METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-22 | — | — | US | disclosed |
| US-20220362367-A1 | MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-11-17 | — | — | US | disclosed |
| US-11305001-B2 | Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3080161-B1 | COMPOSITIONS AND METHODS FOR PHAGOCYTE DELIVERY OF ANTI-STAPHYLOCOCCAL AGENTS | UNIV NEW YORK (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-2096177-A2 | Process for the production of lutein | Metanomics GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130115-A1 | ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-21 | — | — | US | disclosed |
| CN-101421412-A | Process for the production of fine chemicals | METANOMICS GMBH (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-1996231-A2 | ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE | The Texas A & M University System (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1974049-A2 | PROCESS FOR THE CONTROL OF PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007100580-A2 | ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1765857-A2 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| US-6437116-B1 | NUCLEIC ACID IMMUNOGENS; LYME DISEASE TREATMENT, DIAGNOSIS, AND VACCINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362367-A1 | MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF | CD14, TLR8, SPAG5 | SLC1A1 4588/4885GRIK1 4357/4885GRIK2 4221/4885 |
| US-11305001-B2 | Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof | CD14, TLR8, SPAG5 | SLC1A1 4588/4885GRIK1 4357/4885GRIK2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.